Hyperfine (HYPR) EBITDA Margin Growth (3y) (2024 - 2026)
Hyperfine (HYPR) EBITDA Margin Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -343.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 17.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 78.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 487.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -283.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 1,505.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -763.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -184.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Hyperfine | 92.81 Mn | 51.53 Mn | 1.98 Mn | 27,542.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,542.00 |
| Dec 31, 2025 | 81,222.00 |
| Sep 30, 2025 | 30,614.00 |
| Jun 30, 2025 | 115,695.00 |
| Mar 31, 2025 | 106,513.00 |
| Dec 31, 2024 | 551,945.00 |
| Sep 30, 2024 | 411,686.00 |
| Jun 30, 2024 | 377,560.00 |
| Mar 31, 2024 | 203,479.00 |